Back to All Clinical Evidence
Evidence Category:
Treatment Planning

69% of wounds had changes in treatment plans due to using the MolecuLight i:X

85% of wounds with wound bed preparation & high bacterial burden (>104 CFU/g) were impacted by information provided by the i:X

53% of wounds involving antimicrobial stewardship & high bacterial burden (>104 CFU/g) were impacted by information provided by the i:X


The Fluorescence imaging procedure was used to inform advanced wound therapies

Three cases are described in which fluorescence images provided information at the point-of-care

This information was used to guide use of antibiofilm agents, NPWT, and preparation of the wound bed for grafting


Fluorescence imaging was more accurate than clinical judgement in detecting elevated bacterial loads

$7,660 USD per patient was the estimated cost savings from using fluorescence imaging information

This information avoided the application of cellular tissue products on wounds with high levels of bacteria


Wounds were assessed for CSS & fluorescence images were then acquired to determine presence of moderate-to-heavy bacterial loads

Sensitivity of fluorescence imaging was 3-fold higher than CSS (72% vs 22%; p=0.002)

Fluorescence imaging information resulted in treatment plan modifications in 73% of study wounds


This is an initial evaluation of using the MolecuLight i:X in the management of burns

The utility and efficacy of the MolecuLight i:X is evident due to the correlation between microbiology results and fluorescence images

The i:X may be able to detect bacterial load before an infection & subsequent graft failure, thereby shortening lengths of hospital stay & improving overall healing